Concordance involving CA125 and RECIST progression in patients using germline BRCAmutated platinumsensitive relapsed ovarian cancer malignancy treated from the SOLO2 test using olaparib because servicing therapy after reply to radiation: Revision history

Jump to: navigation, search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 January 2024

  • curprev 11:1511:15, 21 January 2024‎ Emerycord91 talk contribs‎ 3,472 bytes +3,472‎ Created page with "Men completed the eu Quality-of-life Five-dimension Five-level level (EQ-5D-5L), EQ-5D visible analogue scale (VAS), and also Brief Soreness Inventory-Short Variety from defined period points during the study. The patient-reported outcome (Expert) populace incorporated adult men whment your antitumor activity and tolerability report associated with talazoparib. The role of emergency coronary angiography (CAG) as well as percutaneous coronary intervention (PCI) pursuing o..."
Retrieved from "https://news.npo.digital/index.php?title=Concordance_involving_CA125_and_RECIST_progression_in_patients_using_germline_BRCAmutated_platinumsensitive_relapsed_ovarian_cancer_malignancy_treated_from_the_SOLO2_test_using_olaparib_because_servicing_therapy_after_reply_to_radiation"